ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination
40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 > 350/mm3 and a viral load <50 copies / mL for at least 6 months).
20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.
Subjects agreeing to be monitored according to the terms of the protocol.
Subjects affiliated to a Social Security scheme or beneficiaries of such a scheme.
Non-volunteers for the 10-year follow-up
Subject under curatorship, guardianship or safeguard of justice.
Parallel
Yellow fever vaccination (STAMARIL)
Biological/VaccineYellow fever vaccination (STAMARIL) for HIV positive and negative subjects
Immuno-virologic criterion
At Months 120 (10years), the antibody titers of neutralizers by PRNT (Plaque reduction neutralization test) and pseudotypes will be determined
Predicting a sustained vaccine response 10 years later.
To study the effect of clinical and biological factors in HIV+ patients (collection of data on: age; clinical examination; heart rate; weight; body temperature; blood pressure; CD4, CD8 and the CD4/CD8 ratio; the nadir and zenith of CD4; the duration of antiretroviral treatment; the duration of HIV infection) on the PRNT titers transformed into logarithm and the percentages of neutralization at ten years, uni and multivariate regressions are used.
Click on the lead sponsor to view all of their trials.
ANRS, Emerging Infectious Diseases
Lead sponsor
Saint-Louis Hospital, Paris, France
Collaborator
Bichat Hospital
Collaborator
Hôpital Cochin
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
